Enanta Pharmaceuticals to Present at 2015 Leerink Global Healthcare Conference

Presentation to be Webcast on February 12 at 10:45 a.m. ET

Leerink Global Healthcare Conference 2015

WATERTOWN, Mass.--()--Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat, or question and answer session, with investors on February 12, 2015 at 10:45 a.m. ET during the 2015 Leerink Global Healthcare Conference in New York.

A live webcast and replay of the question and answer session can be accessed by visiting the “Calendar of Events” section on the “Investors” page of Enanta’s website at www.enanta.com. The replay webcast will be available following the presentation and will be archived for approximately 30 days.

About Enanta

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with AbbVie), NS5A, and nucleotide polymerase – as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Enanta’s lead protease inhibitor, paritaprevir, is part of AbbVie’s recently approved HCV treatment regimen. In addition, Enanta has a preclinical program in non-alcoholic steatohepatitis, or NASH, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver.

Contacts

Investor Contact
Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710
cmiceli@enanta.com

Recent Stories

RSS feed for Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc.